Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Subjects who meet the following criteria may be included in the clinical investigation, if they present with ALL of the following:~1. Subject is able to understand the evaluation and willing to consent and comply with all post-debridement visits and procedures~2. Age 18 years and older. Subjects may be of either sex and of any race or skin type~3. Subjects fulfilling any one or all of the following criteria:~   1. chronic wound(s) below the level of the knee, defined by delayed healing or cellular senescence~  2. acute wound(s) as a result of a surgical procedure, laceration, abrasion or trauma~  3. diabetic foot ulcer(s)~  4. subjects with venous leg ulcers below the knee on the leg or foot with one or more documented failure of maximal medical therapy for their study wound \>30 days such as compression bandages (low elasticity, elastic, multilayered, elastic and non elastic compression)~4. Subjects with the following lab results within 30 days of treatment:~   1. serum albumin level \>20g/L~  2. clinically non significant results of liver function test (LFTs), serum glucose and complete blood count (CBC) with differential~5. Subjects with a Braden Score ≥13-14 (Moderate Risk)~6. Subjects with adequate arterial blood flow \[Ankle-Brachial Index (ABI) \>0.75\]~Exclusion Criteria~Subjects will be excluded from the clinical investigation, if they present with ANY of the following:~1. Subjects that have tunneling wounds~2. Subject presents with an active infection in the study wound, as defined by purulence and:~   1. Fever and leukocytosis~      OR any TWO of the following:~  2. Malodor, pain or tenderness, warmth, erythema, induration, swelling, lymphangitis~3. Infected bone diagnosed by imaging modality (e.g., Magnetic Resonance Imaging (MRI) and/or radiographic images)~4. Subjects whose study wound does not require debridement~5. Cardiac pacemaker or other electronic implant(s)~6. Subjects with irradiate, burn or ischaemic wounds or history of keloids~7. Subjects with vasculitis, non-reconstructive peripheral vascular disease, pyoderma gangrenosum, renal failure or lymphoedema~8. Subjects with uncontrolled bleeding disorder (PT/PTT) and coagulopathy (including those with hemophilia)~9. Subjects taking treatment with any of the following:~   1. Systemic corticosteroids~  2. Immunosuppressive agent(s)~  3. Chemotherapy or Radiation therapy~10. Subjects deemed to require biologic dressing/ skin substitute~11. Terminally ill subjects~12. Subjects that have an immunodeficiency disorder that interferes with wound healing, including Acquired Immunodeficiency Syndrome (AIDS) or know to be infected with Human Immunodeficiency Virus (HIV)~13. Subjects that have chronic skin conditions such as psoriasis, etc.~14. Subjects that reside in a nursing home~15. Subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant~16. Subject is pregnant and/or intending to become pregnant during this clinical investigation period~17. Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within the 12 months prior to enrollment for clinical investigation entry~18. Subject is excluded if they have received an investigational therapy or approved therapy for investigational use within 30 days of surgery~19. Subject is excluded if planning to participate in another research study during the follow-up phase of this study or 84 days after study completion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WoundWand™ Debridement Device (Type: ACTIVE_COMPARATOR): Group I - Coblator IQTM Controller plus WoundWandTM Debridement Device. Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound.
- Standard of Care sharp debridement (Type: ACTIVE_COMPARATOR): Group II - Standard of Care (SoC) surgical (sharp) debridement. Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues